BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a sell rating to a strong sell rating in a research note published on Saturday morning.

Several other equities analysts also recently weighed in on BBOT. HC Wainwright lifted their target price on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Canaccord Genuity Group began coverage on BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $23.00 target price for the company. Finally, Stifel Nicolaus began coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $25.00.

BridgeBio Oncology Therapeutics Price Performance

Shares of NASDAQ:BBOT opened at $8.51 on Friday. The firm has a market cap of $681.74 million, a P/E ratio of -5.60 and a beta of 0.22. The business’s 50-day simple moving average is $8.91. BridgeBio Oncology Therapeutics has a 12-month low of $7.60 and a 12-month high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. On average, sell-side analysts expect that BridgeBio Oncology Therapeutics will post -2.18 EPS for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BBOT. CIBC Private Wealth Group LLC purchased a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd purchased a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $107,000. Squarepoint Ops LLC purchased a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $144,000. Quadrature Capital Ltd purchased a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH purchased a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.